Biocollection of AML, ALL, or high-risk MDS patients at Nantes

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a single-center observational biocollection at Nantes University Hospital. It collects additional blood or bone marrow samples during routine care, after consent, to study tumor biology, microenvironment, and potential biomarkers and targets. Samples are shipped to INSERM for analysis, including transcriptome work and multiparametric flow cytometry on fresh material. The goal is to better understand AML, ALL, and high-risk MDS and to identify information that could improve future treatments. Sampling occurs only when planned as part of patient care and may include up to one extra sample per month for three months after inclusion.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Patient of legal age affected by AML, ALL or MDS regardless of the time of treatment
* Patient who has signed the consent form.
* Patient affiliated with a social security system.

Exclusion Criteria:

* Minor patients.
* Adults under guardianship.
* Protected persons

Where it's running

• Nantes University Hospital
  Nantes, France Recruiting

Study contacts

• Principal investigator: Pierre Peterlin — Nantes University Hospital
• Study coordinator: Pierre Perterlin
• Email: Pierre.PETERLIN@chu-nantes.fr
• Phone: +33 2 40 08 32 71

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Strength Training for Kids with Acute Lymphoblastic Leukemia and Lymphoblastic L lymphoma

  Researchers are testing a structured strength-training program for children and teens recently diagnosed with ALL or lymphoblastic lymphoma to see if it helps with weight gain and physical function during treatment.

  Recruiting UNC Lineberger Comprehensive Cancer Center · Chapel Hill, North Carolina · NCT07634653

• Adding venetoclax to fludarabine–melphalan conditioning for people over 50 with AML or MDS getting a donor stem cell transplant

  This tests whether adding venetoclax to standard fludarabine–melphalan conditioning helps people over 50 with AML or MDS who are having an allogeneic stem cell transplant.

  Recruiting at 18 sites Phase 3 First Affiliated Hospital of Zhejiang University · Fuzhou, Fujian and 17 other locations · NCT07396480

• Prophylactic DLI-X to Prevent Leukemia Relapse After Transplant

  This first-in-human trial tests a prophylactic DLI-X approach to see if it can prevent relapse after matched sibling or haploidentical stem cell transplant in patients with acute leukemias and related blood disorders.

  Recruiting Phase 1 University of Arizona · Tucson, Arizona · NCT07254793

• Orca-T with myeloablative allogeneic stem cell transplant for advanced leukemias and MDS

  This Phase I study tests whether giving Orca-T alongside standard dual‑agent graft‑versus‑host disease prevention is safe in adults (18–70) receiving a myeloablative allogeneic stem cell transplant for acute leukemias or myelodysplastic syndromes.

  Recruiting Phase 1 Stanford University · Palo Alto, California · NCT06551584

• Treatment of adult acute lymphoblastic leukemia with a pediatric regimen in Brazil

  This study is testing a children's leukemia treatment plan to see if it can help adults in Brazil with a specific type of leukemia live longer and have fewer health problems.

  Recruiting Instituto do Cancer do Estado de São Paulo · São Paulo, São Paulo · NCT05959720

• Evaluating treatment effectiveness for relapsed childhood acute lymphoblastic leukemia based on risk groups

  This study is testing different treatment plans for children with relapsed acute lymphoblastic leukemia to see which works best based on their risk level.

  Recruiting at 7 sites Phase 2 Asan Medical Center · Daegu and 9 other locations · NCT05827549

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.